Abstract RF02-03: Trastuzumab deruxtecan (T-DXd) in combination with anastrozole or fulvestrant in patients with HER2-low HR+ advanced/metastatic breast cancer: a Phase 1b, open-label, multicenter, dose-expansion study (DESTINY-Breast08)
Komal Jhaveri(Memorial Sloan Kettering Cancer Center), Sherene Loi(The University of Melbourne), Yen‐Shen Lu(National Taiwan University Hospital), Carey K. Anders(Duke University), Laura Testa, Peter Schmid, Magdalena Wrona, Robyn R. Young(Center for Cancer and Blood Disorders), Seock‐Ah Im(Seoul National University), I. P. Ganshina, Yiwen Zhang(The First People's Hospital of Shunde), Fabrice André(Inserm), Caron Lloyd(AstraZeneca (Netherlands)), Erika Hamilton(Sarah Cannon)
Cited by 12
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k